Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 5/20 | 0.33 |
| ▸ | NPFFR2 | Q9Y5X5 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857161 | 0.88 | KDM4E (0.32) | ALDH1A1AKT1 | |
| SCHEMBL25857174 | 0.86 | ALDH1A1 (0.45) | ALDH1A1AKT1KMT2A | |
| SCHEMBL19388140 | 0.77 | OPRM1 (0.41) | ALDH1A1AKT1MAPT | |
| SCHEMBL25857137 | 0.77 | OPRM1 (0.41) | ALDH1A1AKT1MAPT | |
| SCHEMBL25857181 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KMT2AMAPT | |
| SCHEMBL24746656 | 0.72 | ALDH1A1 (0.45) | ALDH1A1AKT1 | |
| SCHEMBL24746668 | 0.71 | ALDH1A1 (0.44) | ALDH1A1AKT1 | |
| SCHEMBL24746667 | 0.70 | ALDH1A1 (0.43) | ALDH1A1AKT1 | |
| SCHEMBL24747003 | 0.69 | ALDH1A1 (0.43) | ALDH1A1AKT1 | |
| SCHEMBL25857056 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KMT2AMAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801228-B2 | Modified guanidine-containing polymers for biologic delivery | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230225982-A1 | MODIFIED GUANIDINE-CONTAINING POLYMERS FOR BIOLOGIC DELIVERY | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225982-A1 | MODIFIED GUANIDINE-CONTAINING POLYMERS FOR BIOLOGIC DELIVERY | GMPS, RNMT, GUCY1A1 | ALDH1A1 1829/4885AKT1 4171/4885NPFFR1 4135/4885 |
| US-11801228-B2 | Modified guanidine-containing polymers for biologic delivery | GMPS, RNMT, GUCY1A1 | ALDH1A1 1829/4885AKT1 4171/4885NPFFR1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.